ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
3,1,Viral mutation identified,Virus identification and serology,Microbiology and serology investigations,Inv,N
3,2,Virologic failure,Infections NEC,Infections - pathogen unspecified,Infec,N
4,1,Pathogen resistance,Infections NEC,Infections - pathogen unspecified,Infec,N
4,2,Virologic failure,Infections NEC,Infections - pathogen unspecified,Infec,N
5,1,Pathogen resistance,Infections NEC,Infections - pathogen unspecified,Infec,N
5,2,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
5,3,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
6,1,Abnormal dreams,Parasomnias,Sleep disorders and disturbances,Psych,N
6,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
6,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
6,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
6,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
6,6,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
7,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
8,1,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
8,2,Injection site nodule,Injection site reactions,Administration site reactions,Genrl,N
8,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
9,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
9,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
9,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
9,4,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
10,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
10,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
10,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
10,4,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
11,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
11,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
11,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
11,4,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
12,1,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
12,2,Flank pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
12,3,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
13,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
14,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
15,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
16,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
17,1,Amenorrhoea,Menstruation with decreased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
18,1,Amenorrhoea,Menstruation with decreased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
19,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
20,1,Injection site nodule,Injection site reactions,Administration site reactions,Genrl,N
21,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
21,2,Viral load abnormal,Virus identification and serology,Microbiology and serology investigations,Inv,N
22,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
23,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
23,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
23,3,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
23,4,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
23,5,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
23,6,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
23,7,HLA-B*5701 assay positive,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
23,8,Headache,Headaches NEC,Headaches,Nerv,N
23,9,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
23,10,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
23,11,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
23,12,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
23,13,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
23,14,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
23,15,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
23,16,Stridor,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
23,17,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
23,18,Throat tightness,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
23,19,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
24,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
25,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
26,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
27,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
28,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
29,1,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
29,2,Headache,Headaches NEC,Headaches,Nerv,N
29,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
30,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
31,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
32,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
32,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
32,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
33,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
34,1,Amenorrhoea,Menstruation with decreased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
34,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
34,3,Menopausal symptoms,Menopausal effects NEC,Menopause related conditions,Repro,N
35,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
36,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
37,1,Amenorrhoea,Menstruation with decreased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
37,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
37,3,Menopause,Age related issues,Age related factors,SocCi,N
38,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
38,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
39,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
39,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
39,3,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
40,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
41,1,Pathogen resistance,Infections NEC,Infections - pathogen unspecified,Infec,N
41,2,Viral mutation identified,Virus identification and serology,Microbiology and serology investigations,Inv,N
41,3,Virologic failure,Infections NEC,Infections - pathogen unspecified,Infec,N
42,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
42,2,Postoperative wound infection,Infections NEC,Infections - pathogen unspecified,Infec,N
42,3,Tenoplasty,Tendon therapeutic procedures,Soft tissue therapeutic procedures,Surg,N
43,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
44,1,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
45,1,Blood HIV RNA increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
45,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
46,1,Tuberculosis,Tuberculous infections,Mycobacterial infectious disorders,Infec,N
46,2,Type 2 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
46,3,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
47,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
48,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
49,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
50,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
51,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
52,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
52,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
53,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
54,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
54,2,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
54,3,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
54,4,Live birth,"Normal pregnancy, labour and delivery","Pregnancy, labour, delivery and postpartum conditions",Preg,N
54,5,Pathogen resistance,Infections NEC,Infections - pathogen unspecified,Infec,N
54,6,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
54,7,Vertical infection transmission,Infectious transmissions,Ancillary infectious topics,Infec,N
54,8,Viral mutation identified,Virus identification and serology,Microbiology and serology investigations,Inv,N
55,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
56,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
57,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
57,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
57,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
58,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
59,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
60,1,Malabsorption,Malabsorption syndromes,Malabsorption conditions,Gastr,N
61,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
61,2,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
62,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
62,2,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
63,1,Transaminases increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
64,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
64,2,Viral mutation identified,Virus identification and serology,Microbiology and serology investigations,Inv,N
65,1,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
66,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
66,2,Small for dates baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
67,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
67,2,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
67,3,Panic reaction,Panic attacks and disorders,Anxiety disorders and symptoms,Psych,N
68,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
68,2,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
68,3,Panic reaction,Panic attacks and disorders,Anxiety disorders and symptoms,Psych,N
69,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
70,1,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
71,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
72,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
73,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
74,1,Fine motor skill dysfunction,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
74,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
74,3,Polyneuropathy,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
74,4,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
75,1,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
76,1,Blood HIV RNA increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
77,1,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
78,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
78,2,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
79,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
79,2,Exposure via skin contact,Pathways and sources of exposure,"Exposures, chemical injuries and poisoning",Inj&P,N
79,3,Injection site discharge,Injection site reactions,Administration site reactions,Genrl,N
79,4,Injection site nodule,Injection site reactions,Administration site reactions,Genrl,N
80,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
80,2,Mass,Mass conditions NEC,Tissue disorders NEC,Genrl,N
80,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
81,1,Nodule,Mass conditions NEC,Tissue disorders NEC,Genrl,N
82,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
82,2,Pregnancy on oral contraceptive,Unintended pregnancies,"Pregnancy, labour, delivery and postpartum conditions",Preg,N
82,3,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
83,1,Pathogen resistance,Infections NEC,Infections - pathogen unspecified,Infec,N
83,2,Product use in unapproved therapeutic environment,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
83,3,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
84,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
84,2,Pathogen resistance,Infections NEC,Infections - pathogen unspecified,Infec,N
84,3,Product use in unapproved therapeutic environment,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
84,4,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
85,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
86,1,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
86,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
87,1,Skin hypopigmentation,Hypopigmentation disorders,Pigmentation disorders,Skin,N
87,2,Vitiligo,Hypopigmentation disorders,Pigmentation disorders,Skin,N
88,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
89,1,Trigeminal neuralgia,Trigeminal disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
90,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
90,2,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
91,1,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
92,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
92,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
93,1,Body mass index increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
93,2,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
93,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
93,4,Limb discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
94,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
95,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
95,2,Virologic failure,Infections NEC,Infections - pathogen unspecified,Infec,N
96,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
96,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
97,1,Viraemia,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
98,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
98,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
98,3,Psychiatric symptom,Psychiatric symptoms NEC,Psychiatric and behavioural symptoms NEC,Psych,N
99,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
99,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
100,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
100,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
101,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
101,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
101,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
101,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
102,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
102,2,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
103,1,Abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
104,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
105,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
105,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
106,1,Virologic failure,Infections NEC,Infections - pathogen unspecified,Infec,N
107,1,Virologic failure,Infections NEC,Infections - pathogen unspecified,Infec,N
108,1,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
109,1,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
109,2,Virologic failure,Infections NEC,Infections - pathogen unspecified,Infec,N
110,1,Injection site cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
110,2,Injection site hypoaesthesia,Injection site reactions,Administration site reactions,Genrl,N
110,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
111,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
112,1,Appendicectomy,Large intestine therapeutic procedures,Gastrointestinal therapeutic procedures,Surg,N
113,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
113,2,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
113,3,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
113,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
113,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
114,1,Appendicectomy,Large intestine therapeutic procedures,Gastrointestinal therapeutic procedures,Surg,N
115,1,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
115,2,Virologic failure,Infections NEC,Infections - pathogen unspecified,Infec,N
116,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
116,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
117,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
117,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
117,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
118,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
118,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
118,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
119,1,Skin infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
120,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
120,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
120,3,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
120,4,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
120,5,Myalgia,Muscle pains,Muscle disorders,Musc,N
120,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
121,1,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
121,2,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
121,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
122,1,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
123,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
123,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
123,3,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
123,4,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
123,5,Myalgia,Muscle pains,Muscle disorders,Musc,N
124,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
125,1,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
126,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
126,2,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
126,3,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
126,4,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
126,5,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
126,6,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
126,7,Myalgia,Muscle pains,Muscle disorders,Musc,N
127,1,Lymphoma AIDS related,Lymphomas unspecified NEC,Lymphomas NEC,Neopl,Y
127,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
128,1,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
129,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
129,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
130,1,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
131,1,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
132,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
132,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
133,1,Abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
133,2,Mass,Mass conditions NEC,Tissue disorders NEC,Genrl,N
134,1,Nodule,Mass conditions NEC,Tissue disorders NEC,Genrl,N
135,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
135,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
136,1,Nodule,Mass conditions NEC,Tissue disorders NEC,Genrl,N
137,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
137,2,Pathogen resistance,Infections NEC,Infections - pathogen unspecified,Infec,N
137,3,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
137,4,Viral mutation identified,Virus identification and serology,Microbiology and serology investigations,Inv,N
138,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
138,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
139,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
139,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
139,3,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
140,1,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
140,2,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
141,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
142,1,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
143,1,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
144,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
145,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
145,2,Oral mucosal blistering,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
146,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
146,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
146,3,Nerve compression,Mononeuropathies,Peripheral neuropathies,Nerv,N
146,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
147,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
147,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
148,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
149,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
149,2,Toxic skin eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
149,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
150,1,Virologic failure,Infections NEC,Infections - pathogen unspecified,Infec,N
151,1,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
151,2,Blood triglycerides increased,Triglyceride analyses,Lipid analyses,Inv,N
152,1,Abnormal weight gain,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
153,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
153,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
153,3,Headache,Headaches NEC,Headaches,Nerv,N
153,4,Myalgia,Muscle pains,Muscle disorders,Musc,N
154,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
155,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
156,1,Pathogen resistance,Infections NEC,Infections - pathogen unspecified,Infec,N
156,2,Virologic failure,Infections NEC,Infections - pathogen unspecified,Infec,N
157,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
158,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
158,2,Muscle discomfort,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
158,3,Nodule,Mass conditions NEC,Tissue disorders NEC,Genrl,N
158,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
158,5,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
159,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
160,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
161,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
162,1,Gingival pain,"Gingival disorders, signs and symptoms NEC",Dental and gingival conditions,Gastr,N
162,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
163,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
164,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
165,1,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
166,1,Product use in unapproved therapeutic environment,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
166,2,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
167,1,Skin hypertrophy,Skin hyperplasias and hypertrophies,Cornification and dystrophic skin disorders,Skin,N
168,1,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
168,2,Electrocardiogram T wave inversion,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
169,1,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
170,1,Blood HIV RNA increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
